61 results
8-K
EX-3.2
THRX
Theseus Pharmaceuticals Inc
14 Feb 24
Completion of Acquisition or Disposition of Assets
10:44am
, administrative, legislative, investigative or other nature (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director or an officer … to indemnification and to the advancement of expenses to any employee or agent of the Corporation.
Section 6.8 Nature of Rights. The rights conferred upon
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
, purchase order, license, sublicense, commitment or undertaking of any nature, which, in each case, is legally binding upon a party or on any of its … tax of any kind or any charge of any kind in the nature of (or similar to) taxes whatsoever, including any interest, penalty, or addition thereto
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
30 Jan 24
Third party tender offer statement (amended)
8:23am
of the Section 302 tests are satisfied. Due to the factual nature of these tests, U.S. Holders are urged to consult their own tax advisors to determine whether … , and such questions are inherently factual in nature. Accordingly, Holders are urged to consult with their tax advisors regarding this issue.
Pursuant
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
of the reasons supporting the Transactions is forward-looking in nature. This information should be read in light of the reasons discussed in Item 8 under … as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors
SC TO-T
EX-99
Concentra Merger Sub II, Inc.
10 Jan 24
Third party tender offer statement
8:51am
consent in writing. All such Representatives shall (A) be informed by you of the confidential nature of the Evaluation Material, (B) agree to keep
SC TO-T
EX-99
5grfoa9k3a2af0o
10 Jan 24
Third party tender offer statement
8:51am
8-K
EX-2.1
mq8lf6 nbgsz5
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
3m6gxsrt a6remsyx
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-10.2
for0 y8sc6w
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.4
b0wv8mpwd8g
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.1
4bps8mnfopc2 fmi5cf
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.3
cprjg4659t5 2u4
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.1
69i29xo3
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
EX-10.2
g14g13 wpsklc
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm